These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35326715)

  • 1. A Brief Overview of Adaptive Designs for Phase I Cancer Trials.
    Saxena A; Rubens M; Ramamoorthy V; Zhang Z; Ahmed MA; McGranaghan P; Das S; Veledar E
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives.
    Sverdlov O; Wong WK
    Ther Innov Regul Sci; 2014 Sep; 48(5):601-612. PubMed ID: 30231452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current design of oncology phase I clinical trials: progressing from algorithms to statistical models.
    Braun TM
    Chin Clin Oncol; 2014 Mar; 3(1):2. PubMed ID: 25842080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.
    Le Tourneau C; Gan HK; Razak AR; Paoletti X
    PLoS One; 2012; 7(12):e51039. PubMed ID: 23251419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
    Wages NA; Conaway MR
    Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
    Yuan Z; Chappell R
    Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C; Bardet A; Geoerger B; Paoletti X
    Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
    Lin R; Yin G
    Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.
    Lin Y; Shih WJ
    Biostatistics; 2001 Jun; 2(2):203-15. PubMed ID: 12933550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.